Skinvisible Signs License Agreement for Leading Topical Pain Reliever

2007-04-11 | 03:47

Skinvisible, Inc. has signed an agreement to license a new topical analgesic formula with Invisicare, its patented polymer delivery system, to DRJ Group Inc., makers of Stopain. Stopain, a leading over-the-counter topical pain reliever in the $250 million topical analgesic market, will be extending its product line with a new cream formulation that incorporates Invisicare as its delivery system. The addition of Invisicare will keep this product on the skin for an extended period of time, four hours or more, providing on-going relief to people suffering from muscle stiffness, arthritis or muscle strains. “We are very pleased with this partnership with Skinvisible as their delivery system brings added value to our product and ultimately to our customers that use Stopain,” said Mr. Robert Miller, president and chief executive officer of DRJ Group Inc. “By including Invisicare, we are offering our customers a product that is different from anything else currently on the market. We expect this advantage to be well received by both the trade and the customer.” “This licensing agreement with DRJ Group is a notable step for Skinvisible as our brand Invisicare will now have nation-wide exposure to consumers in 25,000 pharmacies,” said Mr. Terry Howlett, president and chief executive officer of Skinvisible. “We look forward to working closely with the Stopain group to find more opportunities to incorporate our technology with their pain relief products.”